

April 5, 2010

To those concerned

R-Tech Ueno, Ltd.  
(Code No.4573, Osaka Securities Exchange; Hercules)  
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo  
Representative: Yukihiro Mashima,  
Representative Director & President  
Contact: Koji Nakamura, Business Management Department;  
TEL: 03-(3596) 8011

### Notification Regarding the Application for Marketing Approval of Latanoprost Eye Drops 0.005% in Japan

We are pleased to announce that R-Tech Ueno has applied for market approval of Latanoprost eye drops 0.005% in Japan.

R-Tech Ueno has applied for market approval of Latanoprost Eye Drops 0.005% in Japan as a therapeutic drug for glaucoma and ocular hypertension.

Taking advantage of our unique drug formulation techniques which we have built through development of new drugs, in the Latanoprost Eye Drops 0.005% applied for market approval, the concentration of the preservative (benzalkonium chloride) which is reported to cause various adverse reactions has been markedly reduced compared to that of the original drug.

We have manufactured and marketed Rescula<sup>®</sup> Eye Drops 0.12% as a new therapeutic drug for glaucoma and ocular hypertension since 1994. We have not only provided a steady supply of safe products to the patients but also have proactively conducted formulation change of Rescula<sup>®</sup> Eye Drops 0.12% to provide a better product to the patients. In prostaglandin related therapeutic drugs for glaucoma and ocular hypertension, there are Rescula<sup>®</sup> Eye Drops 0.12% of the prostone drugs and the prost drugs as represented by latanoprost. Prostone drugs are chosen mainly for patients of early glaucoma because of their high safety and prost drugs are chosen for patients who need further ocular pressure reduction. By adding Latanoprost Eye Drops 0.005%, which has a different action mechanism from Rescula<sup>®</sup> Eye Drops 0.12%, to our product lines of therapeutic drugs for glaucoma and ocular hypertension, creative usage of prostaglandin related drugs depending on clinical states will become possible. We would like to make contributions to the treatment of more patients by offering more options.

Hereafter in the overseas market, we will aim to apply for marketing approval while seeking a distributor of our Latanoprost Eye Drops 0.005% which has added a new twist to the original drug.

- About Rescula® Eye Drops 0.12%

It is the first therapeutic drug for glaucoma and ocular hypertension in the world that contains prostone, a metabotropic prostaglandin derivative. Rescula® Eye Drops 0.12% has a pharmacological effect as an ion channel opener. There are reports that Rescula® Eye Drops 0.12% has not only an ocular pressure decreasing action but also an optic nerve protective action (*in vitro*) and an action to improve ocular blood flow in normal tension glaucoma. It has been approved in 45 countries all over the world since it was marketed in 1994. In 2009, due to formulation change, the concentration of the preservative (benzalkonium chloride) which is reported to cause various adverse reactions has been greatly reduced using our unique technique.

- About Latanoprost Eye Drops 0.005%

It is a prost drug, a prostaglandin derivative, for glaucoma and ocular hypertension. The action mechanism is different from Rescula® Eye Drops 0.12%. It acts on the FP receptor and has an excellent ocular pressure decreasing effect.

- About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of marketing and R&D of drugs. Under leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and selling and developing pharmaceutical products through the eyes of doctors.” We are promoting development of new drugs of unmet medical needs (medical needs that are not fulfilled yet) which the government recommends and assists, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).

Rescula® eyedrop 0.12% that causes less topical and systemic adverse reactions, demonstrates steady ocular pressure decreasing action by twice a day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow increasing mechanism.